Archives

Understanding The IgA Nephropathy Patient Journey
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Understanding The IgA Nephropathy Patient Journey
Background:
IgA Nephropathy (IgAN) is the most common form of primary glomerulonephritis1. The most common signs and symptoms that patients experience are proteinuria and hematuria1. In addition, patients experience significant psychosocial symptoms which impact their daily life.2 Despite the paucity of available treatment options for IgA nephropathy, currently there are many ongoing clinical trials to evaluate new potential options for patients.2
Did You Know?
KDIGO Guidelines recommend clinical trial enrollment as a second line treatment option.3 Many patients are willing to participate in clinical trials; however, a high percentage are unaware or not eligible of the opportunity.2
Why Attend This Webinar?
Learn about the IgA Nephropathy patient journey directly from an IgAN patient and nephrology healthcare provider, Kelly Chen.
What You Will Learn
- Overview of IgA Nephropathy (IgAN), including prevalence, clinical presentation, disease symptoms and diagnosis1
- Discuss the psychosocial symptoms of IgAN and impact on daily life2
- Review current KDIGO guidelines for management of IgAN3
- Discuss the patient experience and perceptions of clinical trials for IgAN2
References:
- Cheung CK et al. Front.Nephrol. 2024; 3:1346769
- Feldman DL et al. The Voice of the Patient. Externally Led Patient–Focused Drug Development Meeting on IgA Nephropathy. https://www.igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf . December 8, 2020. Accessed on May 14, 2024.
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int. 2021;100(4S):S1-S276.
Speakers

Sayna Norouzi, MD
Loma Linda University Medical Center*
Dr. Sayna Norouzi is an assistant professor Medicine and clinical nephrologist at Loma Linda university medical center. She completed her fellowship at Baylor College of Medicine in Houston, TX. She is the founder and director of glomerular diseases clinics in Loma Linda. She is also the co-director of online GlomCon Glomerular Diseases fellowship program. She has been selected as the educator of the year for three consecutive years and is a member of Alpha Omega Alpha medical honor society. She is a special interest in glomerular diseases and is involved in multiple research projects and clinical trials.

Kelly Chen, NP-BC
Kelly Chen is a patient living with IgA Nephropathy as well as a nephrology nurse practitioner. She first received her education from the University of Pennsylvania’s School of Nursing and Wharton School, studying nursing & healthcare management. From first working as a hospital nurse for a few years then transitioning to healthcare consulting, she leveraged her training in both fields. She then went on to complete her graduate nurse practitioner training also at Penn and served as a frontline worker in a medical ICU during the COVID-19 pandemic in New York City at NYU Langone Health. After the pandemic and with her IgAN diagnosis, she returned to her hometown in the San Francisco Bay Area and decided to pivot to caring for kidney patients like herself, working as an ambulatory nephrology nurse practitioner at Stanford Health Care. For the IgAN Foundation, she currently serves as the Medical & Scientific Advisory Board Member as well as the Asian American Engagement Director.
Moderators

Marla Dallal, PharmD, RPH
Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.

Hannah N. Lambert, PharmD
Hannah N. Lambert is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. She earned her Doctor of Pharmacy and completed her clinical residency training at Xavier University of Louisiana College of Pharmacy in New Orleans, LA. Prior to joining Otsuka, Dr Lambert was a clinical pharmacist at Ochsner Health in Digital Medicine.
Sayna Norouzi and Kelly Chen are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Marla Dallal and Hannah Lambert are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.